Many life sciences organizations are now analyzing the efficacy and value of their patient support (hub) programs (PSPs), vendors and partnerships that facilitate improved patient outcomes. To ensure the best patient and healthcare provider (HCP) experiences, your PSP provider should serve as a consultative partner, helping navigate trending market changes, technology improvements and opportunities throughout the product lifecycle.
In this Drug Channels article, Senior Vice President of Business Development and Marketing Stacey Little identifies five crucial considerations for your mid-year PSP review that will keep your program ahead of the curve.
Drug Channels is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.